Search by Journal
- HOME
- > Search by Journal
- > Journal of Japanese Medical Society for Lung Surfactant and Biological Interface
Journal of Japanese Medical Society for Lung Surfactant and Biological Interface
Volume 53, Issue / 2022
English Article Japanese Article
- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
Hermansky-Pudlak syndrome 長内和弘 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 1-6, 2022. |
Surprisingly Familiar Interstitial Lung Disease Increasing Due to the Corona Crisis -Humidifier Lung, which is Hardly Recognized as Hypersensitivity Pneumonia-[Machine Translation] (コロナ禍で増加している意外と身近な間質性肺疾患 - 過敏性肺炎として認知されにくい加湿器肺について -) 坂本晋 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 7-12, 2022. |
Current therapy for asthma and COPD. From controlling current symptoms to reducing future risks. Hiroto Matsuse Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 13-17, 2022. |
Secondary alveolar proteinosis 石井晴之 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 19-19, 2022. |
Hereditary alveolar proteinosis 鈴木拓児 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 20-21, 2022. |
Hermansky-Pudlak syndrome 長内和弘 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 22-22, 2022. |
About the condition of a patient of the pulmonary alveolar microlithiasis and a future treatment strategy 齋藤充史 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 23-23, 2022. |
The distance until OAS1 abnormality symptom discovery 長和俊 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 24-24, 2022. |
Alveolar cells reproduction from iPS cells 後藤慎平 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 25-25, 2022. |
Clinical significance of pulmonary surfactant in COVID-19 pneumonia 黒沼幸治 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 26-26, 2022. |
From symptom improvement as of latest treatment - of bronchial asthma, the COPD to future risk reduction - 松瀬厚人 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 27-27, 2022. |
Expectation to strategy of the bronchial asthma inhalation therapy and inhalational steroid medicine (ICS)/long time functionality beta 2 stimulant drug (LABA)/long time functionality anticholinergic drug (LAMA) combination drug (triple preparation) 玉岡明洋 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 28-28, 2022. |
A respiratory organoid cultural method and the application 桂廣亮 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 29-30, 2022. |
Surprisingly Familiar Interstitial Lung Disease Increasing Due to the Corona Crisis - Humidifier Lung, which is Hardly Recognized as Hypersensitivity Pneumonia - 坂本晋 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 31-34, 2022. |
1. Muc5b plays an important role in the hypersensitivity pneumonitis mouse model 岡本師1,2), David A. Schwartz3), 宮崎泰成2) Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 35-36, 2022. |
2. Effect of TNFα and corticosteroids on rat alveolar epithelial cell barrier function 沓澤直賢, 伊藤洋子, 河野千夏, 浅野浩一郎 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 37-37, 2022. |
3. The establishment of the organoid derived from the mouse lungs tissue and examination of the usefulness 吉本尚平, 橋本修一 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 38-39, 2022. |
4. Effect of the osteopontin perfection loss in the pulmonary fibrosis mouse model associated with the SFTPC Non-BRICHOS domain mutation in the gene 濡木真一1), 平山文博1), 傳田啓太1), 前隆介1), Yaniv Tomer2), Luis Rodoriges2), Jermy Katzen2), Michael F. Beers2) Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 40-40, 2022. |
5. The artificial composition Adjuvant SF-10 mixture new model corona COVID-19 vaccine derived from pulmonary surfactant can induce the antibody which is effective for phylaxis 木本貴士, 堺聡子, 亀田桂子, 森田涼子, 高橋悦久, 木戸博 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 41-42, 2022. |
6. Physical considerations and droplet experiments on coronavirus infection and pulmonary surfactant 多羅尾範郎 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 43-44, 2022. |
7. Usefulness of pulmonary surfactant protein-D in the differentiation of drug-related pneumonia and bacterial pneumonia 早稲田優子1), 三ツ井美穂1), 島田昭和1), 園田智明1), 山口牧子1), 門脇麻衣子1), 梅田幸寛1), 安斎正樹1), 安井正英2), 石塚全1) Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 45-45, 2022. |
8. Examination of the protection of the pulmonary surfactant protein for dioxin using the human Club cell line (NCI-H441 cells) 秦兼太朗1), 鈴木邦裕1), 柳原豊史1,2), 衛藤大祐1), 安藤裕之1), 古鉄泰彬1), 山本悠造1), 原田英治1), 濱田直樹1) Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 46-46, 2022. |
9. Two cases of autoimmune alveolar proteinosis improved by medical management with awareness of alveolar surfactant clearance 丹生谷究二郎, 木田言, 中村友彦, 西沢知剛, 川辺梨恵, 大場智広, 佐藤新太郎, 山川英晃, 天野雅子, 赤坂圭一, 松島秀和 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 47-47, 2022. |
10. Diagnosis experience of the autoimmune alveolar proteinosis that presented water-clear bronchoalveolar lavage fluid 木下義晃, 吉田祐士, 池田貴登, 宮村拓人, 上田裕介, 串間尚子, 石井寛 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 48-48, 2022. |
11. The case that was given repeated total lung washing therapy for autoimmune alveolar proteinosis 温麟太郎, 中尾明, 原田泰志, 海老規之, 井上博文, 藤田昌樹 Journal of Japanese Medical Society for Lung Surfactant and Biological Interface 53: 49-49, 2022. |